--- title: "Go-To-Market - MedTech Roadmap | MedTech Launch Guide" description: "KOLs, IDN selling, GPO contracting, and the chasm in between. Hospital sales cycles run 12–24 months and route through clinical champions, value-analysis comm" lang: en json-ld: | { "@context": "https://schema.org", "@type": "Article", "headline": "Go-To-Market - MedTech Roadmap", "description": "Hospital sales cycles run 12–24 months and route through clinical champions, value-analysis committees, supply chain, and finance. The fastest medtech launches engineer all four conversations in parallel from day one - not sequentially after FDA clearance.", "url": "https://medtechlaunchguide.com/roadmap/go-to-market", "mainEntityOfPage": "https://medtechlaunchguide.com/roadmap/go-to-market", "articleSection": "Go-To-Market", "isPartOf": { "@type": "CollectionPage", "name": "MedTech Founder Roadmap", "url": "https://medtechlaunchguide.com/roadmap" }, "publisher": { "@type": "Organization", "name": "MedTech Launch Guide", "url": "https://medtechlaunchguide.com" } } --- [Skip to content](#main) [ MedTech Launch Guide Education Hub for Founders ](/) [Roadmap](/roadmap) [Topics](/topics) Tools [Pulse](/pulse)Search ⌘K[Start Here](/start) Search ⌘K [Roadmap](/roadmap)/ [01 · IP Protection](/roadmap/ip-protection)[02 · Regulatory Pathway](/roadmap/regulatory-pathway)[03 · Clinical Evidence](/roadmap/clinical-evidence)[04 · Reimbursement](/roadmap/reimbursement)[05 · Cybersecurity](/roadmap/cybersecurity)[06 · Business Model](/roadmap/business-model)[07 · Go-To-Market](/roadmap/go-to-market) Step 07 of 7 · Roadmap # Go-To-Market KOLs, IDN selling, GPO contracting, and the chasm in between When to start Recruit KOLs during clinical trial; commercial team build at submission Duration Early adopter sites: 6–12 months · Mainstream procurement: 24–36 months Indicative cost USD 1.5M–4M/year per direct sales territory at launch Hospital sales cycles run 12–24 months and route through clinical champions, value-analysis committees, supply chain, and finance. The fastest medtech launches engineer all four conversations in parallel from day one - not sequentially after FDA clearance. ## KOL strategy is the trial strategy Your trial sites become your launch sites become your KOLs become your peer-reviewed evidence engine. Pick principal investigators who publish, present at AHA / RSNA / ACC, and sit on guideline committees in your specialty. ## The IDN selling motion Selling into Integrated Delivery Networks means winning four conversations in sequence: clinical champion → value analysis committee → supply chain procurement → finance/CIO. Skip any one and the deal stalls indefinitely. ## GPO + distributor decisions GPO contracts (Vizient, Premier, HealthTrust) compress your margin but unlock thousands of facilities. Distributors carry your product into smaller hospitals you can't reach directly. Both decisions should be made before you hire the first sales rep. Artifacts to ship - KOL map ranked by publication output and committee influence - Value-analysis dossier (clinical + economic + operational) - GPO contracting strategy (which GPO, which tier, what timing) - Sales territory plan with hospital-level account scoring - Marketing collateral library: IFU, training videos, ROI calculator, case studies Common pitfalls - Hiring a VP Sales before you have a repeatable account-conversion playbook - Skipping the VAC because the clinician 'loves it' - VAC kills loved products weekly - Signing a GPO contract before you understand the volume tier triggers - Underestimating field clinical specialists - they're often more important than reps Primary sources - [AdvaMed - Code of Ethics KOL engagement rules ](https://www.advamed.org/our-work/code-of-ethics/) - [AHRMM - Value Analysis Framework VAC process ](https://www.ahrmm.org/) - [Vizient Largest US GPO ](https://www.vizientinc.com/) - [Premier Inc. Major GPO ](https://www.premierinc.com/) [ Previous Business Model Step 06 · Capital equipment, consumables, SaaS, or service - pick on purpose ](/roadmap/business-model)[ Roadmap complete Back to overview → ](/roadmap) MedTech Launch Guide The independent education hub for medtech innovators bringing devices to the US market - paired with a live pulse of what FDA, CMS, CISA and investors are doing right now. Sponsored by Blue Goat Cyber Pulse - [Live Pulse](/pulse) - [Funding Tape](/pulse#funding) - [Pitch Decks](/pulse#pitch) - [Cybersecurity](/pulse#cyber) - [Post-mortems](/pulse#failure) Learn - [Founder Roadmap](/roadmap) - [Start here: build my plan](/start) - [Regulatory & Quality](/roadmap/regulatory-pathway) - [Funding & Grants](/pulse#funding) - [Clinical evidence](/roadmap/clinical-evidence) - [Reimbursement](/roadmap/reimbursement) - [Topics & tools](/topics) - [Funding quiz](/quiz) - [Investor Directory](/investors) - [FDA user fees & calculator](/mdufa-fees) - [Cyber budget worksheet](/worksheets/cyber-budget) - [Glossary](/glossary) - [Weekly Brief](/#newsletter) Company - [About](/about) - [Editorial policy](/editorial) - [Tip line · Contact](/contact) - [Privacy](/privacy) - [Terms](/terms) Sister sites [MedTech Terms ↗](https://medtechterms.com) medtechterms.com The full MedTech dictionary. Sourced definitions with a page per term, A-Z and category indexes, learning paths, and side-by-side comparisons. [A-Z index →](https://medtechterms.com/a-z)[Categories →](https://medtechterms.com/categories)[Learning paths →](https://medtechterms.com/paths)[Compare terms →](https://medtechterms.com/compare) [Blue Goat Cyber ↗](https://bluegoatcyber.com) bluegoatcyber.com Medical device cybersecurity practice. Threat modeling, SBOMs, penetration testing, and FDA premarket and postmarket submission support. [FDA premarket cyber →](https://bluegoatcyber.com/services/medical-device-cybersecurity/fda-premarket-cybersecurity/)[Penetration testing →](https://bluegoatcyber.com/services/medical-device-cybersecurity/penetration-testing/)[Threat modeling →](https://bluegoatcyber.com/services/medical-device-cybersecurity/threat-modeling/)[Site index →](https://bluegoatcyber.com/site-index) © 2026 MedTech Launch Guide. Editorial independence is non-negotiable. Sponsored content is clearly labelled.